ClinicalTrials.gg
Status unknownNCT01986140SCALPUpdated Jul 27, 2021Results posted

Scalp Cooling to Prevent Chemo-induced Hair Loss

An interventional study of PAXMAN Orbis Scalp Cooler and Control No treatment in Breast Cancer and Alopecia, sponsored by Julie Nangia. Status unknown at 7 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-27.

Sponsored by Julie Nangia · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jul 2021), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Determine that the Orbis Paxman Hair Loss Prevention System is safe and effective in reducing chemotherapy-induced alopecia in woman with breast cancer undergoing neoadjuvant or adjuvant chemotherapy.

Read the detailed description

Cooling the scalp during chemotherapy may help reduce the chances of losing hair during treatment. The investigators are hoping that using the PAXMAN Orbis Scalp Cooling Device may stop patients who are undergoing chemotherapy from losing their hair.

02

Conditions studied

  • Breast Cancer
  • Alopecia

Keywords

  • Breast Cancer
  • Alopecia
  • Scalp
  • Cooling
03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's enrollment of 236 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Julie Nangia is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • New diagnosis of breast cancer stage 1-2
  • Planning to undergo or adjuvant chemotherapy with curative intent
  • Chemotherapy must be planned for at least 4 cycles of full-dose anthracycline or taxane based chemotherapy regimen,
  • Defined as one of the following regimens: - Adriamycin 60mg/m2 with cyclophosphamide 600mg/m2 - Epirubicin 90-100mg/m2 with cyclophosphamide 600mg/m2 - Doxorubicin 50mg/m2 with 5-Fluroruacil 500mg/m2 and Cyclophosphamide 500mg/m2 - Paclitaxel 80mg-90/m2 weekly (every three weeks constitute a cycle), or 175 mg/m2 every 2-3 weeks as a single agent - Docetaxel 100mg/m2 as a single agent - Docetaxel 75mg/m2-100mg/m2 with pertuzumab and traztuzumab at standard doses - Docetaxel 75mg/m2 with cyclophosphamide 600mg/m2 - Docetaxel 75mg/m2 with carboplatin AUC of 6 and trastuzumab at standard doses
  • Concurrent traztuzumab at standard doses is allowed
  • Concurrent pertuzumab at standard doses is allowed
  • Administration of chemotherapy on a dose dense schedule is allowed as clinically indicated.
  • Subjects must have TSH collected within 1 year prior to treatment and found within normal range.
  • If patient has a history of diabetes, must be drawn within 3 months prior to treatment and found to be within normal limits.
  • CBC and CMP should be done within 4 weeks prior to treatment and found to be within acceptable limits.

Exclusion criteria

Exclusion Criteria:

  • Stage 3 or 4 breast cancer or any other concurrent including hematological malignancies (i.e. leukemia or lymphoma)
  • Baseline alopecia (defined v4.0 grade > 0, see appendix B for CTCAE v4.0 scale)
  • Subjects with cold agglutinin disease or cold urticaria
  • Subjects who are scheduled for bone marrow ablation chemotherapy
  • Subjects receiving chemotherapy with concurrent anthracycline and taxane (AT or TAC)
  • Male gender
  • Age >= 70 years
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
236 participants (actual)

Study arms

  • Experimental
    PAXMAN Orbis Scalp Cooler

    Scalp Cooling

    Device: PAXMAN Orbis Scalp Cooler

  • Other
    Control No treatment

    Control

    Other: Control No treatment

Interventions

  • DevicePAXMAN Orbis Scalp Cooler

    Treatment with Orbis scalp cooling cap

  • OtherControl No treatment

    No treatment to prevent hair loss

    Also known as: No intervention

06

What researchers measure

Primary outcomes

  1. Hair Preservation

    The primary efficacy endpoint will be success in hair preservation, defined as CTCAE v 4 alopecia grade \<2, and will be assessed by a healthcare professional who is blinded to study treatment.

    Time frame: 4 to 8 Months

Secondary outcomes

  1. Time to First Recurrence and Overall Survival

    A safety follow-up for safety data will be done yearly for 5 years looking at time to first recurrence of breast cancer, overall survival, site of first recurrence, and incidence of isolated scalp metastasis. This will be collected during routine clinical observation

    Time frame: 5 years

Other outcomes

  1. Improved Quality of Life

    Improved quality of life as a result of reduced hair loss is a primary motivator for developing the Paxman Scalp Cooling device. Quality of life will be assessed at baseline and 2-3 weeks after each course of chemotherapy. Three widely used and validated scales will be used: the EORTC QLQ C-30, HADS and BIS. Subjects will be evaluated at multiple time points and data will be analyzed using descriptive methods with median and inter quartile rang to assess the effect of treatment group and alopecia status on functioning, quality of life and depression.

    Time frame: 4 to 8 Months

07

Results

Posted Oct 16, 2018

Participant flow

Participant flow — Overall Study
MilestonePAXMAN Orbis Scalp CoolerControl No Treatment
Started15779
Completed12251
Not completed3528
Withdrew: Withdrawal by subject3125
Withdrew: Alternative treatment11
Withdrew: Found not eligible30
Withdrew: Adverse event01
Withdrew: Progression disease01

Outcome measures

PrimaryHair Preservation

The primary efficacy endpoint will be success in hair preservation, defined as CTCAE v 4 alopecia grade \<2, and will be assessed by a healthcare professional who is blinded to study treatment.

Time frame:
4 to 8 Months
Reported as:
Count of participants · Participants
Hair Preservation
ParticipantsScalp CoolingNon-cooling
success690
failure6154
SecondaryTime to First Recurrence and Overall Survival

A safety follow-up for safety data will be done yearly for 5 years looking at time to first recurrence of breast cancer, overall survival, site of first recurrence, and incidence of isolated scalp metastasis. This will be collected during routine clinical observation

Time frame:
5 years

Results for this outcome have not been posted.

Other pre-specifiedImproved Quality of Life

Improved quality of life as a result of reduced hair loss is a primary motivator for developing the Paxman Scalp Cooling device. Quality of life will be assessed at baseline and 2-3 weeks after each course of chemotherapy. Three widely used and validated scales will be used: the EORTC QLQ C-30, HADS and BIS. Subjects will be evaluated at multiple time points and data will be analyzed using descriptive methods with median and inter quartile rang to assess the effect of treatment group and alopecia status on functioning, quality of life and depression.

Time frame:
4 to 8 Months

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events experienced by subjects were collected from initiation of study device, throughout the study for up to 8 cycle of device use, and within 30 days of the last use of study device. Adverse events through 30 days after study completion were collected.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Scalp Cooling0/137 (0%)0/137 (0%)39/137 (28.5%)
Non-cooling———
Most frequent other events
Showing 10 of 12
Most frequent other events
EventScalp CoolingNon-cooling
headacheNervous system disorders27/137—
nauseaGastrointestinal disorders7/137—
dizzinessNervous system disorders6/137—
scalp painSkin and subcutaneous tissue disorders6/137—
Dry skinSkin and subcutaneous tissue disorders3/137—
PruritusSkin and subcutaneous tissue disorders2/137—
Ear painEar and labyrinth disorders1/137—
chillsGeneral disorders1/137—
painGeneral disorders1/137—
paresthesiaNervous system disorders1/137—

Baseline characteristics

Age, Continuous
Age, Continuous(years)Scalp CoolingNon-coolingTotal
Mean50.4 ± 10.150.6 ± 10.650.4 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Scalp CoolingNon-coolingTotal
Female15779236
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Scalp CoolingNon-coolingTotal
Hispanic or Latino251237
Not Hispanic or Latino13066196
Unknown or Not Reported213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Scalp CoolingNon-coolingTotal
American Indian or Alaska Native000
Asian5510
Native Hawaiian or Other Pacific Islander000
Black or African American191029
White13062192
More than one race000
Unknown or Not Reported325
Region of Enrollment
Region of Enrollment(participants)Scalp CoolingNon-coolingTotal
United States15779236
08

Study locations

7 sites
  • Hematology & Oncology Associates of Northern New Jersey
    Morristown, New Jersey 07962, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Texas Oncology - Medical City Dallas
    Dallas, Texas 75230, United States
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • USOncology / Texas Oncology-Memorial City
    Houston, Texas 77024, United States
  • Lester and Sue Smith Breast Center at Baylor College of Medicine
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Chevli N, Wang K, Haque W, Schwartz MR, Nangia J, Sasaki J, Farach AM, Hatch SS, Butler EB, Teh BS. Prognostic Impact of Radiation Therapy in Pure Mucinous Breast Carcinoma. Clin Breast Cancer. 2022 Oct;22(7):e807-e817. doi: 10.1016/j.clbc.2022.06.005. Epub 2022 Jul 7. PubMed 35915020 ↗
  • Nangia J, Wang T, Osborne C, Niravath P, Otte K, Papish S, Holmes F, Abraham J, Lacouture M, Courtright J, Paxman R, Rude M, Hilsenbeck S, Osborne CK, Rimawi M. Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. JAMA. 2017 Feb 14;317(6):596-605. doi: 10.1001/jama.2016.20939. PubMed 28196254 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Patients are aware of whether or not they are using the cooling device and can tell if they have hair loss.

Supporting information: Informed consent form

Time frame: At completion of their participation.

Access criteria: Patients know if they are wearing the device or not.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Feb 2017, 32 months.

Results were first posted in Oct 2018, 1 year 8 months after primary completion.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 32 months is close to that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2013
First posted
Nov 18, 2013
StartActual
May 15, 2014
Primary completionActual
Feb 10, 2017
CompletionEst.
Dec 2022
Results first posted
Oct 16, 2018
Last update
Jul 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01986140
Lead sponsor
Julie Nangia
Responsible party
Julie Nangia (Assistant Professor, Baylor Breast Care Center) — Sponsor-investigator
First posted
Nov 18, 2013
Start date
May 15, 2014
Primary completion
Feb 10, 2017
Completion
Dec 2022 (estimated)
Results posted
Oct 16, 2018
Last update
Jul 27, 2021

Study contacts

Julie Nangia, M.D.
principal investigator · Baylor College of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion